Amgen's Raised Forecast Still Requires a Strong Second Half

Amgen lifted its 2026 outlook after broad drug growth, but reaching the revenue midpoint still requires about $20.1 billion in second-half sales. to meet guidance.
Amgen raised its 2026 outlook after a strong first half, but the midpoint of the new forecast still requires continued execution across a changing drug portfolio.
The company now expects annual revenue of $38.2 billion to $39.4 billion and adjusted earnings of $22.30 to $23.50 per share. The revenue midpoint of $38.8 billion is $1.0 billion above the previous midpoint, while the adjusted earnings midpoint of $22.90 is $0.50 higher.
Amgen generated roughly $18.7 billion of revenue in the first half, up 7.8% from a year earlier. Reaching the new midpoint would therefore require about $20.1 billion in second-half revenue. Trefis calculates that as roughly 3.6% growth from the comparable period, a lower hurdle than the first-half pace but still dependent on product mix and competitive conditions.
Growth is broad enough to be credible. Six key medicines increased sales by a combined 26% in the latest quarter, and Repatha rose 37% to about $953 million. At the same time, Prolia and Xgeva declined 33% as biosimilars took share. That contrast explains why Amgen can raise guidance while still facing pressure in mature franchises.
The stock's chart provides context, not evidence about future value. Shares were trading above their 50-day and 200-day moving averages in Trefis's market snapshot, indicating positive recent momentum. Yet the reported earnings multiple of roughly 26.8 times exceeded the 22.7 multiple cited for the S&P 500. Both values can change daily, and a premium multiple raises the cost of missing guidance.
Amgen's next report is expected on November 3. Investors should compare second-half sales against the $20.1 billion midpoint requirement and watch whether newer products protect operating margin as older drugs decline.
The raised forecast is constructive because it reduces the amount of growth needed in the back half. It does not remove execution risk. The cleanest confirmation would be continued volume-led growth across several medicines, rather than price or one-time benefits carrying the quarter.
Related News
SoFi's Q3 Test Is Loan Valuation, Not Just an EPS Beat
SoFi enters its October 27 report with strong growth and a $0.60 adjusted EPS target, but loan valuations, credit trends and the durability of fee income will decide whether its lower multiple is justified.
STMicroelectronics' AI Growth Faces a Margin Test on October 29
STMicroelectronics enters earnings with fast data-center growth but weak power-chip margins. Fourth-quarter guidance must show that AI demand can outweigh softer auto and industrial markets.
DraftKings' Prediction-Market Push Is Consuming Its Profit Cushion
DraftKings kept its 2026 EBITDA outlook despite a weak second quarter, but $200 million to $300 million of prediction-market investment makes the November report a test of spending discipline.
MakeMyTrip's Booking Growth Outruns Its Dollar Revenue
MakeMyTrip's gross bookings rose 20.9% at constant currency, but rupee weakness and costly long-haul travel held reported revenue growth to 2.5%. Domestic hotels and buses supplied the momentum.
Chevron’s Next Test Is Cash Flow After a Record Quarter
Chevron enters its October 30 report after record production, refining profits and cash flow. Investors must separate durable operating gains from benefits tied to high oil prices, working capital and unusually strong refining margins.
UnitedHealth’s Recovery Now Depends on Two Different Cost Curves
UnitedHealth raised 2026 guidance as its medical-care ratio improved, but Medicare membership losses and commercial cost growth above 11% create separate tests for the company’s 2027 recovery plan.















Latest comments